Manuel Praga

Manuel Praga is presented as a nephrologist whose contribution to the volume centers on the renal consequences of hepatitis C, especially in patients with AIDS. His chapter places hepatitis C within a chain of clinical problems that runs from persistent viral infection and diagnostic classification to glomerular injury, chronic kidney disease, dialysis, and the difficult balance between antiviral treatment and renal vulnerability. The subject is therefore not merely an authorial name: he represents a clinical perspective in which hepatitis C becomes an emergent problem at the intersection of infectious disease, nephrology, and immunocompromised care.

Identity and Professional Setting

Manuel Praga is identified with the Nephrology Division of Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense de Madrid, in Madrid, Spain. He appears as the author of “Hepatitis C-Induced Renal Disease in Patients with AIDS: An Emergent Problem,” together with Elena Gutiérrez Solís and Enrique Morales. The chapter’s placement in a nephrology volume establishes his principal field: he approaches hepatitis C through kidney disease rather than treating hepatic infection as an isolated specialty concern.

His professional identity is also anchored by the volume’s separate identification of Dr. Manuel Praga as working in the Nephrology Service of Hospital 12 de Octubre. The repeated association with the Madrid institution connects him to a clinical and research environment concerned with the renal manifestations of systemic infection. The evidence does not provide a personal biography, a patient narrative, or a sequence of private experiences; Praga is constructed through institutional affiliation, authorship, and the problems his work organizes.

Clinical Field of Inquiry

Praga’s subject is a disease relationship rather than a single lesion. The surrounding discussion emphasizes that HCV-infected patients, including transplant recipients, have an increased risk of glomerular lesions leading to chronic kidney disease, and that these lesions may occur with or without significant liver disease. A crucial diagnostic boundary governs this account: patients with HCV-associated glomerulonephritis are HCV RNA positive in serum. In this framework, serologic evidence alone cannot carry the entire clinical meaning of infection; active viral replication must be distinguished from resolved infection.

The diagnostic model described in the volume requires both anti-HCV antibodies and detectable HCV RNA to establish chronic active infection. It then calls for assessment of hepatic and extrahepatic effects, including cryoglobulinemia-associated vasculitis, with liver biopsy or noninvasive fibrosis assessment used to evaluate liver damage. FibroScan and other biochemical or morphologic tests may reduce the need for approximately half of liver biopsies and permit yearly follow-up of fibrosis in untreated patients. These details illuminate the kind of medicine represented by Praga’s contribution: classification is not an administrative preliminary but the mechanism by which viral status, renal injury, and treatment eligibility are separated and connected.

Hepatitis C, AIDS, and Renal Injury

The chapter title identifies renal disease induced by hepatitis C in patients with AIDS as an emergent problem. That formulation gives the topic its urgency. HIV-associated vulnerability and HCV infection meet in the kidney, where infection may be associated with glomerular lesions and progression toward chronic kidney disease. The broader evidence reports that the prevalence of HCV seropositivity in case series of membranoproliferative glomerulonephritis is about ten times greater than in HCV-negative patients. It also describes a United States study of 18,002 HCV-infected patients compared with 25,137 controls whose baseline estimated glomerular filtration rate exceeded 60 ml/min/1.73 m²; HCV infection was associated with a higher risk of developing stages 3–5 chronic kidney disease.

The renal burden is measurable in several ways. In another comparison, chronic kidney disease affected 9.6% of anti-HCV-positive patients and 5.1% of HCV-negative patients, while HCV-positive patients reached chronic kidney disease and end-stage renal disease more quickly. Higher baseline viral load independently predicted chronic kidney disease. Cross-sectional data further associated HCV seropositivity with albuminuria, including an adjusted odds ratio of 1.84 among people aged 40–59 years; among those aged at least 60, albuminuria occurred in 46% of HCV-positive individuals compared with 24% of antibody-negative individuals. The evidence is not uniform—some analyses found no association with low estimated glomerular filtration rate—but the pattern supports Praga’s central concern: renal effects can precede or exist independently of advanced liver disease.

From Dialysis Epidemiology to Prevention

Praga’s chapter sits within a volume that treats dialysis as a major environment in the history of HCV transmission. Once HCV was identified as the main cause of non-A, non-B hepatitis in 1989, hemodialysis patients were recognized as a high-risk group. In the early 1990s, their high prevalence reflected both transfusion exposure and suspected nosocomial transmission within dialysis units. Prevalence correlated with time on dialysis independently of transfusion burden, was higher in hemodialysis than in peritoneal or home dialysis, and remained substantial among patients who had never been transfused.

The decline in transfusion risk changed the explanatory center of gravity. The risk of post-transfusion hepatitis C fell from approximately 0.5% per blood unit in the 1980s to around 0.0001%, or one case per million blood units, in the United States. Attention consequently shifted toward infection-control practice. Molecular studies from the mid-1990s used phylogenetic analyses to identify clusters of closely related HCV isolates among patients treated in the same unit, demonstrating nosocomial transmission and helping investigators infer routes of spread.

The preventive conclusion is practical rather than theatrical. Careful hygiene is critical: staff should wash or disinfect hands before and after contact with patients or equipment, wear disposable gloves when caring for patients or touching potentially contaminated surfaces, dispose of single-use items after each patient, disinfect nondisposable equipment, and clean dialysis-station surfaces after every session. The evidence does not support dedicated dialysis machines for HCV-infected patients, and prospective observational studies found that isolating infected patients in separate wards did not protect against transmission after adjustment for confounding factors. Strict infection-control procedures therefore replace isolation as the principal safeguard.

Treatment, Burden, and Significance

The therapeutic setting surrounding Praga’s work is constrained by competing risks. Chronic HCV treatment was based in 2011 mainly on pegylated interferon and ribavirin, with protease-inhibitor triple therapy for genotype 1. Treatment could be considered at any stage, especially when chronic fatigue, necroinflammatory hepatitis, fibrosis above Metavir stage 1, or symptomatic extrahepatic disease such as cryoglobulinemia-associated vasculitis with membranoproliferative glomerulonephritis was present. Yet treatment toxicity was substantial: flu-like symptoms, anemia, neutropenia, depression, and anxiety led to dose reduction in 35–42% of patients and discontinuation in about 30%.

For patients with end-stage renal disease on dialysis, hepatitis C was associated with increased mortality, while its effects extended beyond survival statistics. In a study of 165 regular dialysis patients, 83 of them anti-HCV positive, HCV positivity was independently associated with a reduced mental component score on the SF-36 quality-of-life measure, although no association was found with the physical component score. Fatigue, cognitive impairment, depression, and the psychological burden of diagnosis could therefore coexist with a disease that was often clinically asymptomatic in dialysis patients. Praga’s significance lies in holding these dimensions together: viral detection, kidney pathology, transmission within medical institutions, treatment toxicity, and lived impairment are parts of one clinical landscape rather than separate topics.